MergerJun 22, 2026, 08:02 AM
Aptorum Group & DiamiR Merger Approved by Shareholders
AI Summary
Aptorum Group Limited announced that shareholders of both Aptorum Group and DiamiR Biosciences Corp. have approved their all-stock merger transaction. The merger is anticipated to close before fiscal year 2027, after which the combined entity will operate as Niki BioSolutions, Inc. Additionally, DiamiR Biosciences has entered into a collaboration with AlzLabs Precision Diagnostics to generate blood-based biomarker data for Alzheimer's disease, focusing on protein and microRNA markers.
Key Highlights
- Aptorum Group and DiamiR Biosciences shareholders approved the all-stock merger transaction.
- The merger is expected to close before fiscal year 2027.
- Upon closing, the combined company will be renamed Niki BioSolutions, Inc.
- DiamiR Biosciences announced a collaboration with AlzLabs Precision Diagnostics.
- The collaboration aims to generate protein and microRNA blood-based biomarker data for Alzheimer's disease.
- The study will measure neurodegeneration biomarkers like p-Tau 217, amyloid 42/40, and NfL.
- DiamiR will evaluate these biomarkers with its proprietary CogniMIR® microRNA platform.
Price Impact